MEGAN DAUENHAUER: Open Payments
NPI 1871900464 · METAIRIE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$928 in 45 payments from 13 companies in 2025. Trend: 2023 $823 · 2024 $1,698 · 2025 $928
Food & beverage: $928
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $177 |
| Otsuka America Pharmaceutical, Inc. | 6 | $120 |
| ABBVIE INC. | 6 | $111 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| Neurocrine BioSciences, Inc. | 3 | $82 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Alkermes, Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
Products named: INVEGA, VRAYLAR, REXULTI, FANAPT, INGREZZA, Auvelity, SPRAVATO, UZEDY.
Industry payments across LA — which companies pay providers there.
